AANS Neurosurgeon | Volume 26, Number 1, 2017

Advertisement

Investigational Immunotherapy Drug Shrinks Tumors in High-risk Neuroblastoma Patients

Bookmark and Share

In a study of 34 children and teenage patients, neuroblastoma tumors shrank, some dramatically, after receiving an experimental monoclonal antibody produced on the St. Jude Children’s Research Hospital campus where the study is still underway. After completing therapy, 13 patients showed no evidence of disease. “The early response is very promising, among the best that we have seen against neuroblastoma, but we still have a long way to go,” said furst author Wayne Furman, MD, a member of the St. Jude Department of Oncology. “Will this translate into more clues? We hope so, but the answer is several years away.” To read more, click here.

Calendar/Courses

Microsurgery Course Zurich
March 29-April 1, 2017; Zurich, Switzerland

12th World Congress on Brain Injury
March 29-April 1, 2017; New Orleans

2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.

Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany

Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.

Interactive Calendar

Comments are closed.